# Fulgent Genetics (FLGT) — Earnings

FLGT · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/flgt/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.58 |
| EPS estimate | −$0.46 |
| EPS surprise | −26.09% |
| Revenue surprise | −9.16% |
| Revenue | $85.4M |
| Revenue estimate | $94.0M |
| Reported | Jul 30, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1674930/000119312526326136/flgt-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/7d463c0d-b371-0b41-f6cd-cb2ed09a1509.html) |

Fulgent Genetics reported Q2 2026 results on July 30, 2026. It posted a loss of $0.58 per share, wider than the $0.46 loss expected, a 26.09% miss. Revenue was $85.4 million, below the $94.0 million consensus by 9.16%. A year earlier, in Q2 2025, Fulgent earned $0.07 per share. Revenue rose about 4% from $81.8 million, to the highest in the table.

The record here is short, ten quarters from Q1 2024. In that span Fulgent earned $0.49 per share in 2024 and $0.41 in 2025, with a quarterly high of $0.31 in Q3 2024. Revenue grew from $283.4 million in 2024 to $322.7 million in 2025, about 14% more. 2026 has turned the other way. After a profit of $0.16 in Q4 2025, the company lost $0.36 per share in Q1 2026 and $0.58 in Q2, a first-half loss of $0.94. Fulgent beat the EPS estimate in the eight quarters from Q1 2024 to Q4 2025 then missed in both 2026 quarters.

Q3 results came on November 8, 2024 and November 7, 2025. That points to early November 2026 for the next report. It will show whether the losses of the first half continue.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Jul 30, 2026 | −$0.46 | −$0.58 | -26.09% | $94.0M | $85.4M |
| Q1 2026 | May 1, 2026 | −$0.35 | −$0.36 | -3.39% | $68.1M | $71.1M |
| Q4 2025 | Feb 27, 2026 | $0.03 | $0.16 | 436.91% | $85.4M | $83.3M |
| Q3 2025 | Nov 7, 2025 | −$0.22 | $0.14 | 162.44% | $81.4M | $84.1M |
| Q2 2025 | Aug 1, 2025 | −$0.18 | $0.07 | 137.88% | $76.2M | $81.8M |
| Q1 2025 | May 2, 2025 | −$0.18 | $0.04 | 122.30% | $71.3M | $73.5M |
| Q4 2024 | Feb 28, 2025 | −$0.12 | $0.04 | 132.60% | $74.9M | $76.2M |
| Q3 2024 | Nov 8, 2024 | −$0.15 | $0.31 | 301.56% | $71.7M | $71.7M |
| Q2 2024 | Aug 2, 2024 | −$0.30 | $0.15 | 150.22% | $69.1M | $71.0M |
| Q1 2024 | May 3, 2024 | −$0.32 | −$0.01 | 96.86% | $65.4M | $64.5M |

## Frequently Asked Questions

### When did Fulgent Genetics (FLGT) last report earnings?

Fulgent Genetics last reported on Jul 30, 2026, covering fiscal Q2 2026.

### Did FLGT beat earnings estimates?

No. Fulgent Genetics reported EPS of −$0.58 for Q2 2026 against a −$0.46 estimate — a 26.09% miss.

### How much revenue did FLGT report last quarter?

Fulgent Genetics reported $85.4M in revenue for Q2 2026, against a consensus estimate of $94.0M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).